HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling

HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling
  • Agile Therapeutics Inc's AGRX Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.
  • H.C. Wainwright expects prescription acceleration soon with non-retail channel ramping and Washington forcing coverage with the Affordable Care Act provisions assuring women straightforward, no-cost access to contraceptives. 
  • The analyst has raised the price target to $5 from $2.50 and reiterated a Buy. 
  • Related: Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla.'
  • Management indicates that Afaxys with meaningful institutional orders were likely also stirred by Roe. Large accounts, having switched to Twirla from high-dose Xulane, are still working down the remaining Xulane inventory. 
  • The analyst thinks that if Twirla accelerates along with a lower cost-base, exiting this year, 2024 could potentially break even and re-rate the shares.
  • Also, additional consolidation in the revenue-generating women's health space, thus potential Agile strategic optionality. 
  • Price Action: AGRX shares are down 3.70% at $0.66 during the market session on the last check Tuesday.

Posted In: BriefsBiotechNewsPenny StocksHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneral